Temat: "Prostatic Neoplasms" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
Autorzy :: Sweeney CJ; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: .
Martin AJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; Concord Cancer Centre, Concord Repatriation General Hospital, Concord, Australia; Chris O'Brien Lifehouse RPA, Sydney, Australia.
Begbie S; Port Macquarie Base Hospital, Port Macquarie, NSW, Australia; Mid North Coast Cancer Institute Port Macquarie, Port Macquarie, NSW, Australia.
Chi KN; BC Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada.
Chowdhury S; Guy's and St Thomas' NHS Foundation Trust Biomedical Research Centre, CRUK and King's College London, UK; Sarah Cannon Research UK, London, UK.
Coskinas X; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
Frydenberg M; Monash University, Melbourne, Australia; Australian Urology Associates, Melbourne, Australia.
Hague WE; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
Horvath LG; Chris O'Brien Lifehouse RPA, Sydney, Australia; University of Sydney, Sydney, Australia.
Joshua AM; Kinghorn Cancer Centre, St Vincents Hospital, Sydney, Australia; Garvan Institute of Medical Research, Sydney, Australia.
Lawrence NJ; Auckland City Hospital, Auckland, New Zealand.
Marx GM; University of Sydney, Sydney, Australia; Sydney Adventist Hospital, Wahroonga, Australia.
McCaffrey J; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland.
McDermott R; Cancer Trials Ireland, Dublin, Ireland; St. Vincent's University Hospital, Dublin, Ireland; University College Dublin, Ireland.
McJannett M; ANZUP Cancer Trials Group, Australia.
North SA; Cross Cancer Institute, Edmonton, AB, Canada; University of Alberta, Edmonton, AB, Canada.
Parnis F; Adelaide Cancer Centre, Adelaide, Australia; University of Adelaide, Adelaide, Australia.
Parulekar W; Canadian Cancer Trials Group (CCTG) Queen's University, Kingston, ON, Canada.
Pook DW; Monash University, Melbourne, Australia; Monash Health, Melbourne, Australia.
Reaume MN; University of Ottawa, Ottawa, ON, Canada; Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Sandhu SK; Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Melbourne, Australia.
Tan A; Waikato District Health Board, Hamilton, New Zealand.
Tan TH; Royal Adelaide Hospital, Adelaide, Australia.
Thomson A; Royal Cornwall Hospital, Truro, Cornwall, UK.
Tu E; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
Vera-Badillo F; Kingston Health Sciences Center, Kingston, ON, Canada; Canadian Cancer Trials Group, Kingston, ON, Canada.
Williams SG; Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Melbourne, Australia.
Yip S; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
Zhang AY; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; Chris O'Brien Lifehouse RPA, Sydney, Australia; Macquarie University, Sydney, Australia.
Zielinski RR; Orange Health Service, Central West Cancer Care Centre, Orange, Australia; Western Sydney University, Sydney, Australia.
Davis ID; Monash University, Melbourne, Australia; Eastern Health, Melbourne, Australia.; Pokaż więcej
Corporate Authors :: ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Źródło :: European urology [Eur Urol] 2021 Sep; Vol. 80 (3), pp. 275-279. Date of Electronic Publication: 2021 May 22.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Androgen Antagonists*/therapeutic use
Antineoplastic Agents*/therapeutic use
Benzamides*/therapeutic use
Neoplasms, Second Primary*/drug therapy
Neoplasms, Second Primary*/mortality
Nitriles*/therapeutic use
Phenylthiohydantoin*/therapeutic use
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/mortality
Prostatic Neoplasms*/secondary
Thiohydantoins*/therapeutic use
Clinical Trials as Topic ; Humans ; Male ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/secondary ; Survival Analysis
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer.
Autorzy :: Choi SY; Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102 Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea.
Lim B; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, Republic of Korea.
Chi BH; Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102 Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea.
Lee W; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, Republic of Korea.
Kim JH; Department of Urology, Hanil General Hospital, Seoul, Republic of Korea.
Kyung YS; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, Republic of Korea.
You D; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, Republic of Korea.
Kim CS; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, Republic of Korea.; Pokaż więcej
Źródło :: Medicine [Medicine (Baltimore)] 2021 Aug 06; Vol. 100 (31), pp. e26833.
Typ publikacji :: Journal Article
MeSH Terms :: Prostatectomy*/adverse effects
Prostatectomy*/methods
Prostatic Neoplasms*/blood
Prostatic Neoplasms*/mortality
Prostatic Neoplasms*/pathology
Prostatic Neoplasms*/therapy
Radiotherapy*/adverse effects
Radiotherapy*/methods
Androgen Antagonists/*therapeutic use
Aged ; Biomarkers, Tumor/blood ; Combined Modality Therapy/methods ; Humans ; Kaplan-Meier Estimate ; Male ; Neoplasm Staging ; Outcome and Process Assessment, Health Care ; Patient Selection ; Proportional Hazards Models ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/diagnosis ; Prostatic Neoplasms, Castration-Resistant/epidemiology ; Republic of Korea/epidemiology ; Risk Assessment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Autorzy :: Smith MR; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Hussain M; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Saad F; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Fizazi K; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Sternberg CN; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Crawford ED; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Kopyltsov E; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Park CH; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Alekseev B; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Montesa-Pino Á; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Ye D; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Parnis F; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Cruz F; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Tammela TLJ; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Suzuki H; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Utriainen T; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Fu C; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Uemura M; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Méndez-Vidal MJ; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Maughan BL; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Joensuu H; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Thiele S; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Li R; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Kuss I; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).
Tombal B; From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (M.R.S.); the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); the University of Montreal Hospital Center, Montreal (F.S.); Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France (K.F.); the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York (C.N.S.); the University of California San Diego School of Medicine, La Jolla (E.D.C.); the Clinical Oncologic Dispensary of Omsk Region, Omsk (E.K.), and P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.) - both in Russia; Norton Cancer Institute, Louisville, KY (C.H.P.); La Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen Victoria, Instituto de Investigación Biomédica de Málaga, Malaga (A.M.-P.), and Maimonides Institute for Biomedical Research of Córdoba, Reina Sofía University Hospital, Cordoba (M.J.M.-V.) - both in Spain; Fudan University Shanghai Cancer Center, Shanghai (D.Y.), and Liaoning Cancer Hospital and Institute, Shenyang (C.F.) - both in China; Ashford Cancer Centre Research, Kurralta Park, SA, Australia (F.P.); Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo (F.C.); Tampere University Hospital and Tampere University, Tampere (T.L.J.T.), Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki (T.U.), and Orion Pharma, Espoo (H.J.) - all in Finland; Toho University Sakura Medical Center, Chiba (H.S.), and Osaka University Hospital, Osaka (M.U.) - both in Japan; the Huntsman Cancer Institute, Salt Lake City (B.L.M.); Bayer, Berlin (S.T., I.K.); Bayer HealthCare, Whippany, NJ (R.L.); and the Division of Urology, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels (B.T.).; Pokaż więcej
Corporate Authors :: ARASENS Trial Investigators
Źródło :: The New England journal of medicine [N Engl J Med] 2022 Mar 24; Vol. 386 (12), pp. 1132-1142. Date of Electronic Publication: 2022 Feb 17.
Typ publikacji :: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :: Androgen Receptor Antagonists/*therapeutic use
Prostatic Neoplasms/*drug therapy
Pyrazoles/*therapeutic use
Aged ; Aged, 80 and over ; Androgen Antagonists/therapeutic use ; Androgen Receptor Antagonists/adverse effects ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Docetaxel/adverse effects ; Docetaxel/therapeutic use ; Drug Therapy, Combination ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Metastasis/drug therapy ; Neutropenia/chemically induced ; Proportional Hazards Models ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant ; Pyrazoles/adverse effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids.
Autorzy :: Lee S; Department of Urology, University of California San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.; Rady Children's Hospital, San Diego, CA 92123, USA.
Mendoza TR; Department of Urology, University of California San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Burner DN; Department of Urology, University of California San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Muldong MT; Department of Urology, University of California San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Wu CCN; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.; Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Arreola-Villanueva C; Department of Urology, University of California San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Zuniga A; Department of Urology, University of California San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Greenburg O; Department of Urology, University of California San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Zhu WY; Department of Urology, University of California San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Murtadha J; Department of Urology, University of California San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Koutouan E; Department of Urology, University of California San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Pineda N; Department of Urology, University of California San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Pham H; Department of Urology, University of California San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Kang SG; Department of Urology, Korea University College of Medicine, Seongbuk-Gu, Seoul 02841, Korea.
Kim HT; Department of Urology, School of Medicine, Kyungpook National University, Daegu 41944, Korea.
Pineda G; Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Lennon KM; Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Cacalano NA; Department of Radiation Oncology, University of California, Los Angeles, CA 90095, USA.
Jamieson CHM; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.; Department of Urology, Korea University College of Medicine, Seongbuk-Gu, Seoul 02841, Korea.
Kane CJ; Department of Urology, University of California San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Kulidjian AA; Scripps MD Anderson Cancer Center, La Jolla, CA 92093, USA.
Gaasterland T; Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA 92093, USA.; Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Jamieson CAM; Department of Urology, University of California San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.; Pokaż więcej
Źródło :: International journal of molecular sciences [Int J Mol Sci] 2022 Mar 16; Vol. 23 (6). Date of Electronic Publication: 2022 Mar 16.
Typ publikacji :: Journal Article
MeSH Terms :: Bone Neoplasms/*genetics
Gene Expression Profiling/*methods
Gene Expression Regulation, Neoplastic/*genetics
Organoids/*metabolism
Prostatic Neoplasms, Castration-Resistant/*genetics
Androgens/pharmacology ; Angiotensin-Converting Enzyme 2/genetics ; Angiotensin-Converting Enzyme 2/metabolism ; Animals ; Benzamides/pharmacology ; Bone Neoplasms/metabolism ; Bone Neoplasms/secondary ; COVID-19/genetics ; COVID-19/metabolism ; COVID-19/virology ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Male ; Mice ; Nitriles/pharmacology ; Phenylthiohydantoin/pharmacology ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/pathology ; Receptors, Virus/genetics ; Receptors, Virus/metabolism ; SARS-CoV-2/metabolism ; SARS-CoV-2/physiology ; Serine Endopeptidases/genetics ; Serine Endopeptidases/metabolism ; Transplantation, Heterologous ; Virus Internalization
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 5 5.

Tytuł :: Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists.
Autorzy :: Bonde TM; Department of Urology, Ryhov Hospital, Jönköping, Sweden.
Westerberg M; Department of Mathematics, Uppsala University, Uppsala, Sweden.
Aly M; Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.; Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden.
Eklund M; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Adolfsson J; Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Bill-Axelson A; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Garmo H; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Stattin P; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Robinson D; Department of Urology, Ryhov Hospital, Jönköping, Sweden.; Pokaż więcej
Źródło :: Scandinavian journal of urology [Scand J Urol] 2022 Jun; Vol. 56 (3), pp. 169-175. Date of Electronic Publication: 2022 May 12.
Typ publikacji :: Journal Article
MeSH Terms :: Prostatic Neoplasms*/pathology
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Androgen Antagonists/therapeutic use ; Gonadotropin-Releasing Hormone/therapeutic use ; Humans ; Male ; Orchiectomy ; Prostate-Specific Antigen
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer.
Autorzy :: Arnold P; SAIL Databank, Swansea University Medical School, Swansea, UK.
Penaloza-Ramos MC; Janssen-Cilag Ltd, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK. .
Adedokun L; Janssen-Cilag Ltd, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK.
Rees S; SAIL Databank, Swansea University Medical School, Swansea, UK.
Lockhat M; Janssen-Cilag Ltd, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK.
Spary L; SAIL Databank, Swansea University Medical School, Swansea, UK.
Watkins A; SAIL Databank, Swansea University Medical School, Swansea, UK.
Gnanapragasam V; Divison of Urology, Department of Surgery & Cambridge Urology Translational Research and Clinical Trials Office, University of Cambridge, Cambridge, UK.
Crabb SJ; Cancer Sciences Unit, University of Southampton, Southampton, UK.; Pokaż więcej
Źródło :: Scientific reports [Sci Rep] 2021 Nov 12; Vol. 11 (1), pp. 22151. Date of Electronic Publication: 2021 Nov 12.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Treatment Outcome*
Prostate-Specific Antigen/*blood
Prostatic Neoplasms, Castration-Resistant/*epidemiology
Prostatic Neoplasms, Castration-Resistant/*pathology
Age Factors ; Aged ; Aged, 80 and over ; Androgen Antagonists/therapeutic use ; Cohort Studies ; Humans ; Incidence ; Male ; Neoplasm Metastasis ; Prostatic Neoplasms/epidemiology ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/mortality ; Retrospective Studies ; Wales/epidemiology
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 7 7.

Tytuł :: Metastatic Prostate Cancer: Treatment Options.
Autorzy :: Achard V; Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.; Faculty of Medicine, Geneva University, Geneva, Switzerland.
Putora PM; Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland.; Faculty of Medicine, University of Bern, Bern, Switzerland.
Omlin A; Department of Medical Oncology and Haematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Zilli T; Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.; Faculty of Medicine, Geneva University, Geneva, Switzerland.
Fischer S; Department of Medical Oncology and Haematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.; Pokaż więcej
Źródło :: Oncology [Oncology] 2022; Vol. 100 (1), pp. 48-59. Date of Electronic Publication: 2021 Nov 15.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Antineoplastic Agents/*therapeutic use
Immunotherapy/*methods
Prostatic Neoplasms/*therapy
Radiotherapy/*methods
Clinical Trials as Topic ; Combined Modality Therapy ; Humans ; Male ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/therapy ; Radiopharmaceuticals/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer.
Autorzy :: Byeon S; Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea.
Kim H; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.
Jeon HG; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Seo SI; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Jeon SS; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Lee HM; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Lee SI; Internal Medicine, Dankook University College of Medicine, Cheonan, Chungcheongnam-do, Korea.
Park SH; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea. .; Pokaż więcej
Źródło :: BMC cancer [BMC Cancer] 2021 Nov 29; Vol. 21 (1), pp. 1281. Date of Electronic Publication: 2021 Nov 29.
Typ publikacji :: Clinical Trial, Phase II; Journal Article
MeSH Terms :: Androgen Antagonists/*administration & dosage
Antineoplastic Agents/*administration & dosage
Docetaxel/*administration & dosage
Prostatic Neoplasms/*drug therapy
Aged ; Aged, 80 and over ; Androgen Antagonists/adverse effects ; Anemia/chemically induced ; Antineoplastic Agents/adverse effects ; Diarrhea/chemically induced ; Disease-Free Survival ; Docetaxel/adverse effects ; Drug Administration Schedule ; Fatigue/chemically induced ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Nail Diseases/chemically induced ; Neutropenia/chemically induced ; Pneumonia/chemically induced ; Prospective Studies ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/blood ; Prostatic Neoplasms, Castration-Resistant ; Stomatitis/chemically induced
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 9 9.

Tytuł :: Preparation of Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House.
Autorzy :: Guleria M; Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
Amirdhanayagam J; Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
Sarma HD; Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
Rallapeta RP; Department of Nuclear Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati, 517507 Andhra Pradesh, India.
Krishnamohan VS; Department of Nuclear Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati, 517507 Andhra Pradesh, India.
Nimmagadda A; Department of Nuclear Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati, 517507 Andhra Pradesh, India.
Ravi P; Department of Nuclear Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati, 517507 Andhra Pradesh, India.
Patri S; Department of Nuclear Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati, 517507 Andhra Pradesh, India.
Kalawat T; Department of Nuclear Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati, 517507 Andhra Pradesh, India.
Das T; Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.; Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India.; Pokaż więcej
Źródło :: BioMed research international [Biomed Res Int] 2021 Nov 20; Vol. 2021, pp. 1555712. Date of Electronic Publication: 2021 Nov 20 (Print Publication: 2021).
Typ publikacji :: Journal Article
MeSH Terms :: Dipeptides/*isolation & purification
Dipeptides/*therapeutic use
Heterocyclic Compounds, 1-Ring/*isolation & purification
Heterocyclic Compounds, 1-Ring/*therapeutic use
Lutetium/*isolation & purification
Lutetium/*therapeutic use
Prostate-Specific Antigen/*isolation & purification
Prostate-Specific Antigen/*therapeutic use
Prostatic Neoplasms/*radiotherapy
Radioisotopes/*isolation & purification
Radioisotopes/*therapeutic use
Radiopharmaceuticals/*isolation & purification
Radiopharmaceuticals/*therapeutic use
Animals ; Dipeptides/pharmacokinetics ; Drug Compounding/methods ; Drug Stability ; Freeze Drying ; Heterocyclic Compounds, 1-Ring/pharmacokinetics ; Humans ; In Vitro Techniques ; Lutetium/pharmacokinetics ; Male ; Nuclear Pharmacy/methods ; Pharmacy Service, Hospital ; Positron Emission Tomography Computed Tomography ; Prostate-Specific Antigen/pharmacokinetics ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/diagnostic imaging ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/radiotherapy ; Radiochemistry/methods ; Radiochemistry/standards ; Radioisotopes/pharmacokinetics ; Radiopharmaceuticals/pharmacokinetics ; Rats ; Rats, Wistar ; Tissue Distribution
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 10 10.

Tytuł :: Rates of False-Negative Screening in Prostate Specific Antigen Secondary to 5-Alpha Reductase Inhibitor Usage: A Quality-Improvement Initiative.
Autorzy :: Loloi J; Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Wei M; Albert Einstein College of Medicine, Bronx, NY, USA.
Babar M; Albert Einstein College of Medicine, Bronx, NY, USA.
Zhu D; Albert Einstein College of Medicine, Bronx, NY, USA.
Fram EB; Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Maria P; Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.; Pokaż więcej
Źródło :: International braz j urol : official journal of the Brazilian Society of Urology [Int Braz J Urol] 2022 Jul-Aug; Vol. 48 (4), pp. 688-695.
Typ publikacji :: Journal Article
MeSH Terms :: Prostate-Specific Antigen*/blood
Prostatic Hyperplasia*/diagnosis
Prostatic Hyperplasia*/drug therapy
Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/prevention & control
5-alpha Reductase Inhibitors/therapeutic use ; False Negative Reactions ; Humans ; Male ; Retrospective Studies
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Robot-Assisted Radical Prostatectomy Using the KangDuo Surgical Robot-01 System: A Prospective, Single-Center, Single-Arm Clinical Study.
Autorzy :: Fan S; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China.
Zhang Z; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China.
Wang J; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China.
Xiong S; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China.
Dai X; Department of Urology, Civil Aviation General Hospital, Civil Aviation Medical College of Peking University, Chaoyang District, Beijing, China.
Chen X; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China.
Li Z; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China.
Han G; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China.
Zhu J; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China.
Hao H; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China.
Yu W; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China.
Cui L; Department of Urology, Civil Aviation General Hospital, Civil Aviation Medical College of Peking University, Chaoyang District, Beijing, China.
Shen C; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China.
Li X; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China.
Zhou L; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China.; Pokaż więcej
Źródło :: The Journal of urology [J Urol] 2022 Jul; Vol. 208 (1), pp. 119-127. Date of Electronic Publication: 2022 May 18.
Typ publikacji :: Clinical Study; Journal Article
MeSH Terms :: Prostatic Neoplasms*/complications
Prostatic Neoplasms*/surgery
Robotic Surgical Procedures*/methods
Robotics*
Humans ; Male ; Postoperative Complications/epidemiology ; Postoperative Complications/etiology ; Postoperative Complications/surgery ; Prospective Studies ; Prostatectomy/methods ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer.
Autorzy :: Magnani CJ; School of Medicine, Stanford University, Stanford, California.; Stanford Health Policy, Centers for Health Policy/Primary Care and Outcomes Research, Stanford University, Stanford, California.; Division of Urological Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Hernandez-Boussard T; Department of Medicine, School of Medicine, Stanford University, Stanford, California.
Baker LC; Stanford Health Policy, Centers for Health Policy/Primary Care and Outcomes Research, Stanford University, Stanford, California.; Department of Medicine, School of Medicine, Stanford University, Stanford, California.
Goldhaber-Fiebert JD; Stanford Health Policy, Centers for Health Policy/Primary Care and Outcomes Research, Stanford University, Stanford, California.; Department of Medicine, School of Medicine, Stanford University, Stanford, California.
Brooks JD; Department of Urology, Stanford University, Stanford, California.; Pokaż więcej
Źródło :: The Journal of urology [J Urol] 2022 Jul; Vol. 208 (1), pp. 80-89. Date of Electronic Publication: 2022 Feb 25.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :: Multiparametric Magnetic Resonance Imaging*
Prostatic Neoplasms*/diagnostic imaging
Prostatic Neoplasms*/therapy
Cost-Benefit Analysis ; Humans ; Image-Guided Biopsy/methods ; Magnetic Resonance Imaging/methods ; Male ; Prospective Studies ; Watchful Waiting
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
Autorzy :: Chen K; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
McVey A; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Kasivisvanathan V; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Division of Surgery and Interventional Science, University College London, London, UK.
Jenjitranant P; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Azad A; Division of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
Murphy DG; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia. Electronic address: .; Pokaż więcej
Źródło :: European urology [Eur Urol] 2022 Jul; Vol. 82 (1), pp. 146-147. Date of Electronic Publication: 2022 Mar 25.
Typ publikacji :: Journal Article
MeSH Terms :: Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/pathology
Androgen Receptor Antagonists ; Hormones ; Humans ; Male ; Pyrazoles
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.
Autorzy :: Cyrta J; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.; Department for BioMedical Research, University of Bern, Bern, Switzerland.
Prandi D; Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.
Arora A; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Hovelson DH; Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MA, USA.
Sboner A; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.; HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.
Rodriguez A; Department for BioMedical Research, University of Bern, Bern, Switzerland.; Institute of Pathology, University of Bern, Bern, Switzerland.
Fedrizzi T; Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.
Beltran H; Department of Medicine, Division of Medical Oncology, Weill Cornell Medicine, New York, NY, USA.; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
Robinson DR; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Gopalan A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
True L; Department of Pathology, University of Washington, Seattle, WA, USA.
Nelson PS; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Robinson BD; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Mosquera JM; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Tomlins SA; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Shen R; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Demichelis F; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.; Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.
Rubin MA; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.; Department for BioMedical Research, University of Bern, Bern, Switzerland.; Pokaż więcej
Źródło :: The Journal of pathology [J Pathol] 2022 Jul; Vol. 257 (3), pp. 274-284. Date of Electronic Publication: 2022 Mar 28.
Typ publikacji :: Journal Article
MeSH Terms :: Prostatic Neoplasms*/pathology
Prostatic Neoplasms, Castration-Resistant*/genetics
Prostatic Neoplasms, Castration-Resistant*/pathology
Genomics ; Humans ; Male ; Nuclear Proteins/genetics ; Phylogeny ; Pilot Projects ; Prostatectomy ; Repressor Proteins/genetics
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer.
Autorzy :: Bright JR; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, Maryland.
Lis RT; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, Maryland.
Ku AT; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, Maryland.
Terrigino NT; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, Maryland.
Whitlock NC; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, Maryland.
Trostel SY; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, Maryland.
Carrabba NV; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, Maryland.
Harmon SA; Molecular Imaging Branch, National Cancer Institute, NIH, Bethesda, Maryland.
Turkbey B; Molecular Imaging Branch, National Cancer Institute, NIH, Bethesda, Maryland.
Wilkinson S; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, Maryland.
Sowalsky AG; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, Maryland.; Pokaż więcej
Źródło :: The Journal of urology [J Urol] 2022 Jul; Vol. 208 (1), pp. 90-99. Date of Electronic Publication: 2022 Mar 01.
Typ publikacji :: Journal Article
MeSH Terms :: Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/drug therapy
Androgen Antagonists/therapeutic use ; Androgens ; Humans ; Male ; Neoadjuvant Therapy ; Neoplasm, Residual ; Prostate/pathology ; Prostate-Specific Antigen ; Prostatectomy
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Inhibition of N -Acetyltransferase 10 Suppresses the Progression of Prostate Cancer through Regulation of DNA Replication.
Autorzy :: Ma N; Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, 38 Xueyuan Road, Haidian District, Beijing 100191, China.
Liu H; Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, 38 Xueyuan Road, Haidian District, Beijing 100191, China.
Wu Y; Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, 38 Xueyuan Road, Haidian District, Beijing 100191, China.
Yao M; Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, 38 Xueyuan Road, Haidian District, Beijing 100191, China.
Zhang B; Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, 38 Xueyuan Road, Haidian District, Beijing 100191, China.; Pokaż więcej
Źródło :: International journal of molecular sciences [Int J Mol Sci] 2022 Jun 12; Vol. 23 (12). Date of Electronic Publication: 2022 Jun 12.
Typ publikacji :: Journal Article
MeSH Terms :: Prostatic Neoplasms*/metabolism
Prostatic Neoplasms, Castration-Resistant*/pathology
N-Terminal Acetyltransferases/*metabolism
Acetyltransferases/genetics ; Animals ; Cell Line, Tumor ; Cell Proliferation ; DNA Replication ; Humans ; Male ; Mice ; Mice, Nude
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets.
Autorzy :: Kappel C; Department of Medicine, McMaster University, Hamilton, Canada.
Jiang DM; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada. Electronic address: .
Wong B; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada.
Zhang T; Advanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Selvarajah S; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Warner E; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Hansen AR; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada.
Fallah-Rad N; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada.
Sacher AG; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada.
Stockley TL; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Bedard PL; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada.
Sridhar SS; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada.; Pokaż więcej
Źródło :: Clinical genitourinary cancer [Clin Genitourin Cancer] 2022 Jun; Vol. 20 (3), pp. 278-284. Date of Electronic Publication: 2022 Feb 22.
Typ publikacji :: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/genetics
Prostatic Neoplasms, Castration-Resistant*/pathology
Androgen Antagonists/therapeutic use ; Cohort Studies ; DNA Repair ; Genomics ; Humans ; Male
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer: A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform Protocol.
Autorzy :: Grünwald V; Interdisciplinary Genitourinary Oncology, Department of Urology and Department of Medical Oncology, University Hospital Essen, Essen, Germany.
Ohlmann CH; Department of Urology, Johanniter Hospital Bonn, Bonn, Germany.
Hadaschik B; Department of Urology, University Hospital Essen, Essen, Germany. Electronic address: .; Pokaż więcej
Źródło :: European urology [Eur Urol] 2022 Jun; Vol. 81 (6), pp. 621. Date of Electronic Publication: 2022 Feb 19.
Typ publikacji :: Journal Article; Meta-Analysis
MeSH Terms :: Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/pathology
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/pathology
Abiraterone Acetate/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Benzamides ; Clinical Trials, Phase III as Topic ; Humans ; Male ; Meta-Analysis as Topic ; Nitriles/therapeutic use ; Phenylthiohydantoin/therapeutic use ; Prednisolone/therapeutic use ; Randomized Controlled Trials as Topic ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer.
Autorzy :: Hadadi A; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.
Smith KE; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.
Wan L; Departments of Biostatistics and Bioinformatics, Emory University, Atlanta, GA.
Brown JR; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Russler G; Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Yantorni L; Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Caulfield S; Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Lafollette J; Grady Cancer Center for Excellence, Grady Memorial Hospital, Atlanta, GA.
Moore M; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Grady Cancer Center for Excellence, Grady Memorial Hospital, Atlanta, GA.
Kucuk O; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Grady Cancer Center for Excellence, Grady Memorial Hospital, Atlanta, GA.
Carthon B; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Grady Cancer Center for Excellence, Grady Memorial Hospital, Atlanta, GA.
Nazha B; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Grady Cancer Center for Excellence, Grady Memorial Hospital, Atlanta, GA.
Liu Y; Departments of Biostatistics and Bioinformatics, Emory University, Atlanta, GA.
Bilen MA; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Grady Cancer Center for Excellence, Grady Memorial Hospital, Atlanta, GA. Electronic address: .; Pokaż więcej
Źródło :: Urologic oncology [Urol Oncol] 2022 Jun; Vol. 40 (6), pp. 271.e9-271.e18. Date of Electronic Publication: 2022 Apr 22.
Typ publikacji :: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
MeSH Terms :: Prostatic Neoplasms*/pathology
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Basophils/pathology ; Docetaxel/therapeutic use ; Hormones/therapeutic use ; Humans ; Lymphocytes/pathology ; Male ; Retrospective Studies
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics.
Autorzy :: Eshghi A; From the College of Osteopathic Medicine, Kansas City University, Joplin, MO.
Covington MF; Department of Radiology and Imaging Sciences, University of Utah, Center for Quantitative Cancer Imaging, Huntsman Cancer Institute, Salt Lake City, UT.
Eshghi N; Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR.
Kuo PH; Departments of Medical Imaging, Medicine, and Biomedical Engineering, University of Arizona, Tucson, AZ.; Pokaż więcej
Źródło :: Clinical nuclear medicine [Clin Nucl Med] 2022 Jun 01; Vol. 47 (6), pp. 488-495. Date of Electronic Publication: 2022 Apr 05.
Typ publikacji :: Journal Article
MeSH Terms :: Prostatic Neoplasms*/pathology
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Humans ; Male ; Positron Emission Tomography Computed Tomography/methods ; Precision Medicine ; Radioisotopes/therapeutic use ; Radiopharmaceuticals/therapeutic use
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Prostatic Neoplasms"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język